CMS has recalculated some 2026 Medicare Advantage Star Ratings after a court ruling found an improper calculation for Clover Health’s rating. The change could boost payments for a limited number of insurers, signaling continued operational volatility for risk adjustment metrics tied to court and compliance outcomes. While the item is policy- and payer-focused rather than drug-development, it can directly affect biotech-adjacent healthcare budgets, value-based contracts, and payer behavior that influence coverage and adoption of therapies. The update underscores that rating methodology and legal interpretation can shift reimbursement economics on short timelines—an environment where health systems and downstream vendors must manage changing financial assumptions.